Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Med Virol ; 95(1): e28378, 2023 01.
Article in English | MEDLINE | ID: covidwho-2148394

ABSTRACT

BACKGROUND: To investigate the safety of inactivated COVID-19 vaccine in Chinese pregnant women and their fetuses when inoculated during the peri-pregnancy period. METHODS: Eligible pregnant women were prospectively collected and divided into a vaccine group (n = 93) and control group (n = 160) according to whether they had been vaccinated against COVID-19 within 3 months before their last menstruation period (LMP) and after pregnancy. Demographic data of couples, complications during pregnancy and delivery of pregnant women, and data of newborns at birth were collected. RESULTS: Sixty-six women were vaccinated with a median time of 35.5 (range = 0-91) days before LMP, and 27 women were vaccinated with a median time of 17 (range = 1-72) days after LMP. The incidence of premature rupture of membrane (PROM) in the vaccine group was significantly higher than that in the control group (16.13% vs. 6.88%, p = 0.019). Multivariate logistic regression analysis revealed that maternal peri-pregnancy COVID-19 vaccination was not an independent risk factor for PROM (odds ratio: 2.407, 95% confidence interval: 0.932-6.216, p = 0.069). There was no difference in the incidence of other complications during pregnancy and delivery between the two groups. A total of 253 neonates were delivered, including two cases with congenital abnormalities in each group. The incidence of congenital abnormalities between the two groups was similar (2.15% vs. 1.25%, p = 0.626). There was no difference in neonatal length, weight, head circumference, and Apgar score between the two groups (p > 0.05), but the incidence of neonatal jaundice in the vaccine group was significantly higher than that in the control group (20.43% vs. 7.5%, p = 0.002). Multivariate logistic regression analysis revealed that maternal peri-pregnancy vaccination, postpartum blood loss, cesarean section, 1-min Apgar score, and paternal smoking were independent risk factors for neonatal jaundice. CONCLUSIONS: It is safe for pregnant women and their fetuses to be inoculated the inactivated COVID-19 vaccine during the peri-pregnancy period, but attention should be paid to neonatal jaundice.


Subject(s)
COVID-19 Vaccines , COVID-19 , Jaundice, Neonatal , Pregnancy Complications, Infectious , Female , Humans , Infant, Newborn , Pregnancy , Cesarean Section , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Pregnancy Complications, Infectious/epidemiology , Pregnancy Complications, Infectious/prevention & control , Pregnancy Outcome/epidemiology , Prospective Studies
2.
Chinese Journal of Virology ; 37(4):950-956, 2021.
Article in Chinese | GIM | ID: covidwho-2145387

ABSTRACT

Against the background of the outbreak of coronavirus disease 2019 (COVID-19) . in order to further understand and clarify the current global status and hotspots of the COVID-19, this paper is based on the Web of Science database to search for this topic. As of April 30, 2020, the SCI literature in the field of SARS-CoV-2 will be subjected to a metrological analysis to discuss the research focus and research status of SARS-CoV-2. This research analyzed the research situation of this research field through the information acquisition, processing and analysis of SARS - CoV - 2 related literature, and the application of bibliometrics methods. Statistical analysis data and visual data analysis results showed that a total of 1, 523 documents had been searched with "COVID - 19" as the subject term;at the current stage of research, China ranked first in the number of articles published in this field;University of London, Harvard University and Huazhong University of Science and Technology were among the top three institutions in the world in terms of publication volume;sorting out high-frequency key words to identify the research hotspots as COVID-19, SARS and public health. It is found that Chinese scholars have achieved rapid development in the field of "COV ID-19", and they are at the forefront of the world in terms of the influence of articles and the amount of articles published.

3.
Vaccines (Basel) ; 10(9)2022 Sep 06.
Article in English | MEDLINE | ID: covidwho-2010349

ABSTRACT

China started to implement COVID-19 vaccination programs for children in July 2021. This study investigated the changes in parents' COVID-19 vaccine hesitancy for children before and after the vaccination program rollout. Repeated cross-sectional online surveys among full-time adult factory workers were conducted in Shenzhen, China. This analysis was based on 844 (first round) and 1213 parents (second round) who had at least one child aged 3-17 years. The prevalence of vaccine hesitancy for children aged 3-11 years dropped from 25.9% (first round) to 17.4% (second round), while such a prevalence for children aged 12-17 years dropped from 26.0% (first round) to 3.5% (second round) (p < 0.001). Positive attitudes, a perceived subjective norm, and perceived behavioral control related to children's COVID-19 vaccination were associated with lower vaccine hesitancy in both rounds. In the second round and among parents with children aged 3-11 years, negative attitudes and exposure to information on SARS-CoV-2 infection after receiving a primary vaccine series were associated with higher vaccine hesitancy, while exposure to experiences shared by vaccine recipients and infectiousness of variants of concern were associated with lower vaccine hesitancy. Regular monitoring of vaccine hesitancy and its associated factors among parents should be conducted to guide health promotion.

4.
J Surg Oncol ; 125(4): 596-602, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1592572

ABSTRACT

BACKGROUND AND OBJECTIVES: With increased neoadjuvant therapy recommendations for early-stage breast cancer patients due to the COVID-19 pandemic, it is imperative that molecular diagnostic assays provide reliable results from preoperative core needle biopsies (CNB). The study objective was to determine the concordance of MammaPrint and BluePrint results between matched CNB and surgical resection (SR) specimens. METHODS: Matched tumor specimens (n = 121) were prospectively collected from women enrolled in the FLEX trial (NCT03053193). Concordance is reported using overall percentage agreement and Cohen's kappa coefficient. Correlation is reported using Pearson correlation coefficient. RESULTS: We found good concordance for MammaPrint results between matched tumor samples (90.9%, κ = 0.817), and a very strong correlation of MammaPrint indices (r = 0.94). The concordance of BluePrint subtyping in matched samples was also excellent (98.3%). CONCLUSIONS: CNB samples demonstrated high concordance with paired SR samples for MammaPrint risk classification and BluePrint molecular subtyping, suggesting that physicians are provided with accurate prognostic information that can be used to guide therapy decisions.


Subject(s)
Biomarkers, Tumor/genetics , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Clinical Decision Rules , Genomics , Adult , Aged , Aged, 80 and over , Biopsy, Large-Core Needle , Breast Neoplasms/surgery , Female , Humans , Middle Aged , Neoplasm Staging , Prognosis , Prospective Studies , Reproducibility of Results , Risk Assessment
5.
Medicine (Baltimore) ; 100(1): e24198, 2021 Jan 08.
Article in English | MEDLINE | ID: covidwho-1024163

ABSTRACT

BACKGROUND: With the outbreak of novel coronavirus, the treatment of respiratory diseases has been promoted. In particular, many traditional Chinese medicines, including Chinese patent medicines, have been found to be effective in the treatment of respiratory illness in China. chronic obstructive pulmonary disease (COPD) is one of most common respiratory condition. It is predicted that COPD will be become the third frequent cause of death by 2030. The aim of this study is to assess the efficacy and safety of Shufeng Jiedu Capsule in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). METHODS: According to the search strategy, randomized controlled trials (RCTs) of Shufeng Jiedu Capsule in the treatment of AECOPD were obtained from Cochrane Library, MEDLINE, Embase, CNKI, VIP, CBM, and WANGFANG. Studies were screened according to inclusion and exclusion criteria, and the Cochrane risk bias assessment tool was used to assess the quality of the study. Meta-analysis was performed using Revman 5.4 software. Finally, the evidence level of the results will be evaluated. RESULTS: The purpose of this study was to evaluate the efficacy and safety of Shufeng Jiedu Capsule in the treatment of AECOPD, and to provide basis for clinical rational drug use. CONCLUSION: Our research results of this study could provide reference for clinical decision-making and guiding development in the future COPD patient. INPLASY REGISTRATION NUMBER: INPLASY2020120062.


Subject(s)
Drugs, Chinese Herbal/therapeutic use , Pulmonary Disease, Chronic Obstructive/drug therapy , Research Design , Capsules , Humans , Meta-Analysis as Topic , Systematic Reviews as Topic
SELECTION OF CITATIONS
SEARCH DETAIL